Community Health Media
Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts
Episodes
How is the rapidly changing treatment landscape reshaping second-line ER-positive, HER2-negative metastatic breast cancer care?
In this Special CHM Conversation, Dr. Seth Wander and Dr. Paolo Tarantino discuss the growing number of endocrine therapy options and how clinicians can navigate increasingly complex treatment decisions.
They explore what the newly approved combination of imlunestrant plus abemaciclib means for patients with...
How should clinicians navigate the growing number of treatment options for ESR1-mutated metastatic breast cancer?
Dr. Jason Mouabbi and Dr. Erika Hamilton discuss the evolving treatment landscape for hormone receptor-positive, HER2-negative metastatic breast cancer, with a focus on ESR1 mutations, molecular testing, PROTACs, oral SERDs, and treatment sequencing.
They explore when and how to test for ESR1 mutations, including the role...
How is T-DXd reshaping the treatment pathway for HER2-positive breast cancer?
Drs. Paolo Tarantino and Seth Wander discuss the rapidly evolving role of trastuzumab deruxtecan (T-DXd) across metastatic and early-stage HER2-positive breast cancer.
From the first-line DESTINY-Breast09 data to the neoadjuvant DESTINY-Breast11 and adjuvant DESTINY-Breast05 data, they explore the new opportunities and clinical questions around treatment se...
How is T-DXd changing the treatment landscape for HER2-positive breast cancer?
Drs. Ruta Rao and Irene Kang discuss the evolving role of trastuzumab deruxtecan (T-DXd) across HER2-positive breast cancer, from first-line metastatic disease to neoadjuvant and adjuvant treatment.
They examine data from DESTINY-Breast09, DESTINY-Breast05, and DESTINY-Breast11, along with emerging maintenance strategies from PATINA and HER2CLIMB-05. The c...
How is DESTINY-Breast09 changing the first-line treatment landscape for metastatic HER2-positive breast cancer?
Drs. Jason Mouabbi and Neil Iyengar discuss the evolving role of trastuzumab deruxtecan (T-DXd) plus pertuzumab in first-line metastatic HER2-positive breast cancer and how the DESTINY-Breast09 findings are influencing clinical decision-making.
They examine how this approach compares with the long-standing CLEOPATRA regimen...
With more targeted therapies available for CLL, how are clinicians navigating the growing number of first-line treatment options?
Drs. Kerry Rogers, William Wierda, and Catherine Coombs discuss the evolving CLL treatment landscape, including fixed-duration versus continuous therapy, BTK- and BCL-2 inhibitor–based approaches, and how disease biology, comorbidities, treatment logistics, and patient preferences can guide treatmen...
For more than a decade, THP—established by the landmark CLEOPATRA trial— defined the first-line standard for HER2-positive metastatic breast cancer. Now, DESTINY-Breast09 is changing the conversation.
In this CHM Conversation, Dr. Sonya Reid and Dr. Shruti Singh discuss the evolving first-line treatment landscape and how trastuzumab deruxtecan (T-DXd) plus pertuzumab is reshaping clinical decision-making for patients wit...
Are antibody-drug conjugates becoming the new first-line standard for metastatic triple-negative breast cancer?
At This Moment in Medicine, hosted by Community Health Media, Dr. Senthil Damodaran reviews the latest data moving ADCs earlier in the treatment landscape for metastatic TNBC.
The presentation focuses on TROPION-Breast02, ASCENT-03, and ASCENT-04, comparing datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan with ch...
How should we approach first-line treatment as the HER2-positive metastatic breast cancer landscape rapidly evolves?
At This Moment in Medicine, hosted by Community Health Media, Dr. Mothaffar Rimawi examines how new data are reshaping a treatment landscape long defined by the CLEOPATRA regimen.
From DESTINY-Breast09 to PATINA and HER2CLIMB-05, Dr. Rimawi explores emerging strategies for deeper HER2 and ER pathway inhibition, the rol...
Where should T-DXd fit in the treatment of high-risk, early-stage HER2-positive breast cancer?
At This Moment in Medicine, hosted by Community Health Media, Dr. Michelina Cairo reviews the latest data from DESTINY-Breast11 and DESTINY-Breast05, examining how trastuzumab deruxtecan (T-DXd) could reshape treatment in both the neoadjuvant and adjuvant settings.
From pathologic complete response and invasive disease-free survival to ILD ...
How is adjuvant treatment for ER-positive, HER2-negative breast cancer changing?
At This Moment in Medicine, Dr. Akshjot Puri examines key data from OPTIMA, lidERA, NATALEE, and monarchE—and what these trials could mean for chemotherapy de-escalation, endocrine therapy, ovarian suppression, and CDK4/6 inhibitor use.
From using Prosigna to identify patients who may be able to avoid chemotherapy to the emerging role of oral SERDs...
A new era in HER2-positive metastatic breast cancer is here.Dr. Jason Mouabbi, Dr. Ruta Rao, and Dr. Mark Pegram break down the groundbreaking DESTINY-Breast09 trial and discuss how trastuzumab deruxtecan (T-DXd) plus pertuzumab is redefining first-line treatment.
The conversation explores:
- Why DB09 may replace the CLEOPATRA standard
- The significance of 40+ month median PFS
- Complete response rates and treatment durability
- Managing I...
Can we improve outcomes by changing treatment before radiographic progression occurs?
In this in-depth discussion, Dr. Anne O'Dea and Dr. Mabel Mardones explore how the SERENA-6 trial is reshaping the management of HR-positive, HER2-negative metastatic breast cancer through ctDNA-guided treatment decisions and earlier intervention for emerging ESR1 mutations.
Topics discussed include:
- The clinical impact of the SERENA-6 trial
- Using...
HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it be used across early-stage and into metastatic disease?
In this in-depth discussion, Dr. Rena Callahan and Dr. Aditya Bardia explore how these landmark studies are changing treatment decisions today across neoa...
The first-line treatment landscape for metastatic triple-negative breast cancer is changing rapidly.
Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, and Dr. Ana Garrido-Castro discuss how ADCs are reshaping frontline TNBC care and what the latest clinical evidence means for real-world practice.
The conversation explores:
- The evolution of metastatic TNBC treatment
- Why many patients never reach second-line therapy
- The impact of ASCENT and ...
The treatment landscape for perioperative gastric cancer is changing rapidly.
In this expert roundtable, leading GI oncology specialists discuss the practice-changing impact of the MATTERHORN trial, the role of immunotherapy in resectable gastric cancer, and how emerging data from ASCO 2026 is influencing treatment decisions in both academic and community settings.
Featuring insights from Dr. Zev Wainberg, Dr. Nataliya Uboha, Dr. Sun...
Could EMERALD-3 redefine the treatment paradigm for unresectable hepatocellular carcinoma?
In this special roundtable discussion recorded at ASCO 2026, Dr. Ghassan Abou-Alfa is joined by Dr. Gentry King, Dr. Mehmet Akce, Dr. Pierre Gholam, Dr. Lingling Du, Dr. Adam Burgoyne, Dr. Lipika Goyal, and Dr. Riad Salem to break down the landmark EMERALD-3 study.
The panel explores the scientific rationale for combining transarterial chemoemb...
How are we navigating the evolving landscape of second-line treatment for metastatic HR-positive, HER2-negative breast cancer?
In this full-length discussion, Dr. Ursa Brown-Glaberman and Dr. Karthik Giridhar explore one of the most rapidly evolving areas in breast oncology: treatment selection after progression on first-line endocrine therapy and CDK4/6 inhibitors.
The conversation examines how molecular profiling, ctDNA testing, AK...
How is trastuzumab deruxtecan (T-DXd) reshaping treatment across early-stage and metastatic HER2-positive breast cancer?
Dr. Sarah Premji, Dr. Reshma Mahtani, and Dr. Eleftherios "Terry" Mamounas discuss the practice-changing implications of DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09, exploring how T-DXd is moving earlier in the treatment paradigm and influencing decision-making from the neoadjuvant setting through fir...
Can T-DXd plus pertuzumab finally replace the CLEOPATRA regimen as the new first-line standard for metastatic HER2-positive breast cancer?
In this comprehensive discussion from ASCO 2026, Dr. Jason Mouabbi, Dr. Fengting Yan, and Dr. Paolo Tarantino break down the practice-changing DESTINY-Breast09 data and what it means for treatment sequencing, patient selection and toxicity management. Beyond the clinical trial results, the expert...
Popular Podcasts
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
Listen to 'The Bobby Bones Show' by downloading the daily full replay.
The official podcast of comedian Joe Rogan.
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by Audiochuck Media Company.